Interní Med. 2011; 13(7): 292-295
Biological therapy for non-small-cell lung carcinoma
- Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
The therapeutic outcomes in recent years have shown that the possibilities of conventional chemotherapy have been exhausted and
other combinations of conventional cytostatic drugs are not expected to significantly prolong the survival of patients with NSCLC.
Another option for these patients is a therapy targeted at cell signalling pathways and their modulation. This method of therapeutic
intervention is referred to as biologically targeted therapy. Unlike conventional cytostatic treatment, biological therapy is an approach
at the subcellular level. While manipulating the natural regulatory mechanisms controlling the metabolism, proliferation and migration
of cancer cells, biological therapy uses low-molecular-weight agents, macromolecules as well as immune effector cells. The article deals
with the biological therapy agents that have been approved for use in the Czech Republic.
Keywords: non-small-cell lung carcinoma (NSCLC), biological therapy, prognostic factors, predictive factors
Published: October 1, 2011 Show citation
References
- http://www.svod.cz
- Ginsberg RJ. Lung Cancer. London, BC Decker Hamilton, 2002: 175.
- Marel M, Skácel Z, Špásová I, et al. Diagnostika a léčba nemocných s plicním karcinomem na oddělení TRN ve FN Motol v letech 1998-2003. Stud Pneumol Phtiseol 2004; 64: 289-294.
- Martins SJ, Pereira JR. Clinical Factors and Prognosis in NonSmall Cell Lung Cancer. Am J Clin Oncol 1999; 22: 453-457.
Go to original source... 
Go to PubMed... - Sirohi B, Ashley S, Bortin A, et al. Early Response to Platinum - Based First - Line Chemotherapy in Non-Small Cell Lung Cancer May Predict Suvival. J Thorac Oncol 2007; 2: 735-740. Go to original source... Go to PubMed...
- Molina JR, Dusi AA, Jett JR. Advances in Chemotherapy of Non-small Cell Lung Cancer. Chest 2006; 130: 1211-1219. Go to original source... Go to PubMed...
- Dy GK, Adjei AA. Novel Targets for Lung Cancer Therapy: Part II. J Clin Onco.
- Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 2003; 41: S9-S14. Go to original source... Go to PubMed...
- Mendelsohn J. Targeting the Epidermal Growth Factor Receptor for Cancer Therapy. Journal of Clinical Oncology 2002; 20 (suppl 15): 1-13.
- http://www.cancer.gov/clinicaltrials/results/cetuximabNSCLC0608
- Jonson DH. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer 2003; 41: S23-S28. Go to original source... Go to PubMed...
- Baselga J, Kris M, Yano S, et al. Phase II trial (IDEAL a and IDEAL 2) of ZD1839 (IRESSA) in locally advanced or metastatic non-small-cell lung cancer patients. ESMO, Nice, France, October 18-22, 2002.
- Fukuoka M, Yano S, Giacone G, et al. A multi-institutional randomized phase II trial of gefitinib for previously terated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003; 21: 2237-2246. Go to original source... Go to PubMed...
- Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003; 290: 2149-2158. Go to original source... Go to PubMed...
- Pešek M, Skřičková J, Kolek V, et al. Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. Studia Pneumologica et Pthiseologica. 2009, 69(2): 61-68.
- Pešek M, Teřl M, Krákorová G. Gefitinib - zkušenosti s biologicky cílenou terapií nemalobuněčného karcinomu plic. Stud Pneumol Phtiseol 2004; 64: 117-122.
- Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537. Go to original source... Go to PubMed...
- Lynch TJ, Bell DW, Sordella R, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med 2004; 350: 2129-2139. Go to original source... Go to PubMed...
- Kim ES, Hirsch V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer: a randomised Phase III trial (INTEREST). Lancet 2008; 372: 1809-1818. Go to original source... Go to PubMed...
- Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. 2004; 22: 777-784. Go to original source... Go to PubMed...
- Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a Phase III trial - INTACT 2. J. Clin. Oncol. 2004; 22: 785-794. Go to original source... Go to PubMed...
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 2009; 361(10): 947-957. Go to original source... Go to PubMed...
- Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. Go to original source... Go to PubMed...
- Skřičková J, Pešek M, Zatloukal P, et al. Klinický registr TARCEVA. Klin Okol 2010; 23(5): 361-363.
- Tomíšková M, Skřičková J, Štícha M. Klinické zkušenosti s léčbou erlotinibem u nemocných s pokročilým nemalobuněčným karcinomem plic. Onkologie 2010; 4: 270-276.
- Cappuzzo F, Stelmakh T, Cicenas S, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The Lancet Oncology 2009, 11: 521-529. Go to original source... Go to PubMed...
- Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 2002; 29: 10-14. Go to original source... Go to PubMed...
- Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. Go to original source... Go to PubMed...
- Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27(14): 2415. Go to original source... Go to PubMed...
- Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacuzimab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. Go to original source... Go to PubMed...
- Laskin J, Crino L, Tsai C, et al. MO19390 (SAiL): first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC)-outcome by chemotherapy regimen [abstract C2.5]. J Thorac Oncol 2009; 4(Suppl 1): S359.